Patents by Inventor Robert Murray McKinnell

Robert Murray McKinnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR
    Publication number: 20240158389
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Application
    Filed: October 3, 2023
    Publication date: May 16, 2024
    Inventors: Jennifer Kozak, Ryan Hudson, Gary E.L. Brandt, Robert Murray McKinnell
  • IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS
    Publication number: 20240092758
    Abstract: Provided herein are compounds of formula (I): and pharmaceutically-acceptable salts thereof, where A, W, X, Y and Z are defined in the specification. The compounds of formula (I) and pharmaceutically-acceptable salts thereof are Janus kinase (JAK) inhibitors. Also provided herein are pharmaceutical compositions comprising such compounds; and methods of using such compounds to treat, e.g., inflammatory and fibrotic diseases, including respiratory diseases.
    Type: Application
    Filed: June 24, 2022
    Publication date: March 21, 2024
    Inventors: Robert Murray MCKINNELL, Tom M. LAM, Cameron SMITH, Philip GERKEN, Paul ALLEGRETTI, Gabrielle Elaine DOLGONOS, Christina OWENS
  • Fused pyrimidine pyridinone compounds as JAK inhibitors
    Patent number: 11697648
    Abstract: The disclosure provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The disclosure also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal inflammatory diseases.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: July 11, 2023
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Diana Jin Wang, Anthony Francesco Palermo, Luke Boralsky, Breena Fraga
  • PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR
    Publication number: 20220396573
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Application
    Filed: June 30, 2022
    Publication date: December 15, 2022
    Inventors: Jennifer Kozak, Ryan Hudson, Gary E.L. Brandt, Robert Murray McKinnell
  • BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS
    Publication number: 20220274957
    Abstract: The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: January 12, 2022
    Publication date: September 1, 2022
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Robert Murray McKinnell, Roland Gendron, Lan Jiang, Seok-Ki Choi, Daniel D. Long, Paul R. Fatheree, Daniel Marquess
  • Pyrimidine compound as JAK kinase inhibitor
    Patent number: 11420965
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: August 23, 2022
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Jennifer Kozak, Ryan Hudson, Gary E. L. Brandt, Robert Murray McKinnell
  • Imidazole and triazole containing bicyclic compounds as JAK inhibitors
    Patent number: 11339160
    Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal and other inflammatory diseases.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: May 24, 2022
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Anthony Francesco Palermo
  • PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS
    Publication number: 20220119369
    Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: February 22, 2021
    Publication date: April 21, 2022
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Jerry Nzerem, Marta Dabros, Venkat R. Thalladi, Miroslav Rapta
  • Benzimidazole-carboxamide compounds as 5-HTreceptor agonists
    Patent number: 11254655
    Abstract: The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: February 22, 2022
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventor: Robert Murray McKinnell
  • Fused imidazo-piperidine JAK inhibitor compound
    Patent number: 11160810
    Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: November 2, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Robert Murray McKinnell, Venkat R. Thalladi, Hao Zhang, Paul R. Fatheree, Lan Jiang, Marta Dabros, Jerry Nzerem
  • PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR
    Publication number: 20210214349
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Application
    Filed: March 30, 2021
    Publication date: July 15, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Jennifer Kozak, Ryan Hudson, Gary E.L. Brandt, Robert Murray McKinnell
  • FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS
    Publication number: 20210188844
    Abstract: The disclosure provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The disclosure also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal inflammatory diseases.
    Type: Application
    Filed: November 24, 2020
    Publication date: June 24, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Diana Jin Wang, Anthony Francesco Palermo, Luke Boralsky, Breena Fraga
  • Pyrimidine compound as JAK kinase inhibitor
    Patent number: 10988470
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: April 27, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Jennifer Kozak, Ryan Hudson, Robert Murray McKinnell, Gary E. L. Brandt
  • Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
    Patent number: 10968205
    Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 19, 2019
    Date of Patent: April 6, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Jerry Nzerem, Marta Dabros, Venkat R. Thalladi, Miroslav Rapta
  • IMIDAZOLE AND TRIAZOLE CONTAINING BICYCLIC COMPOUNDS AS JAK INHIBITORS
    Publication number: 20210040085
    Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal and other inflammatory diseases.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 11, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Anthony Francesco Palermo
  • Imidazole and triazole containing bicyclic compounds as JAK inhibitors
    Patent number: 10851102
    Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal and other inflammatory diseases.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: December 1, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Anthony Francesco Palermo
  • PYRIMIDINE COMPOUND AS JAK KINASE INHIBITOR
    Publication number: 20200369660
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
    Type: Application
    Filed: August 12, 2020
    Publication date: November 26, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: JENNIFER KOZAK, RYAN HUDSON, ROBERT MURRAY MCKINNELL, GARY E.L. BRANDT
  • BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS
    Publication number: 20200283408
    Abstract: The invention relates to benzimidazole-carboxamide 5-HT4 receptor agonist compounds of formula (I) wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: May 22, 2020
    Publication date: September 10, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventor: Robert Murray McKinnell
  • IMIDAZOLE AND TRIAZOLE CONTAINING BICYCLIC COMPOUNDS AS JAK INHIBITORS
    Publication number: 20200231590
    Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat gastrointestinal and other inflammatory diseases.
    Type: Application
    Filed: January 22, 2020
    Publication date: July 23, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Robert Murray McKinnell, Erik Fenster, Tom M. Lam, Anthony Francesco Palermo
  • PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS
    Publication number: 20200216423
    Abstract: The invention provides compounds of formula (I): or a pharmaceutically-acceptable salt thereof, wherein the variables are defined in the specification, that are inhibitors of JAK kinases, particularly JAK3. The invention also provides crystalline forms, pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: November 19, 2019
    Publication date: July 9, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: ROBERT MURRAY MCKINNELL, ERIK FENSTER, TOM M. LAM, JERRY NZEREM, MARTA DABROS, VENKAT R. THALLADI, MIROSLAV RAPTA